


AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions and listings of claims in the application:

LISTING OF CLAIMS:

1. (Original) A compound of the general formula I



wherein

A is Ph-Y₍₁₋₃₎ or Ar-X₍₀₋₂₎;

R1 is selected from dimethylamino, diethylamino, di-isopropylamino, pyrrolidino, piperidino, and 4-methyl-piperazino;

Ar is selected from phenyl, 1-naphtyl, 2-naphtyl, 2-pyridyl, 3-pyridyl, 4-pyridyl, 6-quinolinyl, and 5-pyrimidinyl;

X₍₀₋₂₎ represents 0 to 2 substituents selected from C1-C6 branched or unbranched alkyls, C1-C6 branched or unbranched alkyloxy, C1-C6 branched or unbranched acyls, fluoro, chloro, bromo, trifluoromethyl, dimethylamino, diethylamino and trifluoromethoxy;

Y₍₁₋₃₎ represents 1 to 3 substituents selected from fluoro, chloro, bromo, dimethylamino, diethylamino, trifluoromethyl, and methoxy;


Z is O or S;

n is 1-3; and

m is 2-4, or

pharmaceutically acceptable salts of the compounds of the general formula I.

2. (Original) A compound according to claim 1 having the general formula Ia



wherein

R1 is selected from dimethylamino, diethylamino, di-isopropylamino, pyrrolidino, piperidino, and 4-methyl-piperazino;

$Y_{(1-3)}$ represents 1 to 3 substituents selected from fluoro, chloro, bromo, dimethylamino, diethylamino, trifluoromethyl, and methoxy;


Z is O or S;

n is 1-3; and

m is 2-4, or

pharmaceutically acceptable salts of the compounds of the general formula Ia.

3. (Original) A compound according to claim 1 having the general formula Ib



wherein

R1 is selected from dimethylamino, diethylamino, di-isopropylamino, pyrrolidino, piperidino, and 4-methyl-piperazino;

Ar is selected from phenyl, 1-naphtyl, 2-naphtyl, 2-pyridyl, 3-pyridyl, 4-pyridyl, 6-quinolinyl, and 5-pyrimidinyl;

$X_{(0-2)}$ represents 0 to 2 substituents selected from C1-C6 branched or unbranched alkyls, C1-C6 branched or unbranched alkyloxy, C1-C6 branched or unbranched acyls, fluoro, chloro, bromo, trifluoromethyl, dimethylamino, diethylamino and trifluoromethoxy;

$Y_{(1-3)}$ represents 1 to 3 substituents selected from fluoro, chloro, bromo, dimethylamino, diethylamino, trifluoromethyl, and methoxy;

Z is O or S;

n is 1-3; and

m is 2-4, or

pharmaceutically acceptable salts of the compounds of the general formula Ib.

4. (Currently Amended) A compound according to ~~any one of claims 1-3~~ claim 1, wherein

R1 is selected from dimethylamino, diethylamino, diisopropylamino, pyrrolidino, piperidino, 4-methyl-piperazino;

n is selected from 1 and 2;

m is selected from 2 and 3;

$Y_{(1-3)}$ is one substituent selected from fluoro, chloro, bromo, trifluoromethyl, dimethylamino and diethylamino.

5. (Currently Amended) A compound according to ~~any one of claims 1 and 3-4~~
claim 1, wherein

Ar is selected from phenyl, 2-naphthyl and 4-pyridyl,
n is selected from 1 and 2;
m is selected from 2 and 3;
 $Y_{(1-3)}$ is one of the substituents selected from fluoro, chloro, bromo, and tri-fluoromethyl.

6. (Currently Amended) A compound according to ~~any one of claims 1-5~~ claim 1 chosen from the group comprising

1-(2-Diethylamino-ethyl)-3-(3-trifluoromethyl-phenyl)-1-{2-[3-(3-trifluoromethyl-phenyl)-ureido]-ethyl}-urea;

1-(2-Diethylamino-ethyl)-3-(4-trifluoromethyl-phenyl)-1-{2-[3-(3-trifluoromethyl-phenyl)-ureido]-ethyl}-urea;

1-(2-Pyrrolidin-1-yl-ethyl)-3-(4-trifluoromethyl-phenyl)-1-{2-[3-(4-trifluoromethyl-phenyl)-ureido]-ethyl}-urea;

3-(4-Chloro-phenyl)-1-{2-[3-(4-chloro-phenyl)-ureido]-ethyl}-1-(2-pyrrolidin-1-yl-ethyl)-urea;

1-{2-[3-(3-Chloro-phenyl)-1-(2-piperidin-1-yl-ethyl)-ureido]-ethyl}-3-(3-trifluoromethyl-phenyl)-urea;

1-{2-[3-(4-Chloro-phenyl)-ureido]-ethyl}-1-(2-dimethylamino-ethyl)-3-(4-trifluoromethyl-phenyl)-urea;

3-(4-Bromo-phenyl)-1-{2-[3-(4-bromo-phenyl)-ureido]-ethyl}-1-(2-dimethylamino-ethyl)-urea;

1-(2-Diethylamino-ethyl)-1-[2-(3-phenyl-ureido)-ethyl]-3-(4-trifluoromethyl-phenyl)-urea;

1-(2-Piperidin-1-yl-ethyl)-3-(3-trifluoromethyl-phenyl)-1-{2-[3-(3-trifluoromethyl-phenyl)-ureido]-ethyl}-urea;

1-(2-Piperidin-1-yl-ethyl)-3-(4-trifluoromethyl-phenyl)-1-{2-[3-(3-trifluoromethyl-phenyl)-ureido]-ethyl}-urea;

1-{2-[1-(2-Pyrrolidin-1-yl-ethyl)-3-(4-trifluoromethyl-phenyl)-ureido]-ethyl}-3-(3-trifluoromethyl-phenyl)-urea;

1-{2-[3-(4-Bromo-phenyl)-1-(2-diethylamino-ethyl)-ureido]-ethyl}-3-(2,6-dichloro-pyridin-4-yl)-urea;

3-(4-Chloro-phenyl)-1-{2-[3-(4-chloro-phenyl)- ureido]-ethyl}-1-(2-diethylamino-ethyl)-urea;

1-(2-Dimethylamino-ethyl)-3-(4-trifluoromethyl-phenyl)-1-{2-[3-(3-trifluoromethyl-phenyl)-ureido]-ethyl}-urea;

1-(2-Diethylamino-ethyl)-3-(3-fluoro-phenyl)-1-{2-[3-(3-fluoro-phenyl)-ureido]-ethyl}-urea;

1-{2-[1-(3-Pyrrolidin-1-yl-propyl)-3-(4-trifluoromethyl-phenyl)-ureido]-ethyl}-3-(4-trifluoromethyl-phenyl)-urea;

1-{2-[3-(4-Chloro-phenyl)-ureido]-ethyl}-1-(2-diethylamino-ethyl)-3-(4-trifluoromethyl-phenyl)-urea;

1-{2-[3-(4-Chloro-phenyl)-ureido]-ethyl}-1-(2-diisopropylamino-ethyl)-3-(4-trifluoromethyl-phenyl)-urea;

1-{2-[3-(4-Chloro-phenyl)-ureido]-ethyl}-1-(2-piperidin-1-yl-ethyl)-3-(4-trifluoromethyl-phenyl)-urea;

1-(4-Chloro-phenyl)-3-{2-[3-(4-chloro-phenyl)-1-(2-diethylamino-ethyl)-thiouido]-ethyl}-thiourea;

1-{2-[3-(4-Bromo-phenyl)-ureido]-ethyl}-1-(2-diisopropylamino-ethyl)-3-(4-trifluoromethyl-phenyl)-urea;

1-(4-Chloro-phenyl)-3-{2-[1-(2-pyrrolidin-1-yl-ethyl)-3-(4-trifluoromethyl-phenyl)-ureido]-ethyl}-urea;

1-{2-[3-(4-Bromo-phenyl)-ureido]-ethyl}-1-(3-diethylamino-propyl)-3-(4-trifluoromethyl-phenyl)-urea;

1-(2-Dimethylamino-ethyl)-1-[2-(3-phenyl-ureido)-ethyl]-3-(4-trifluoromethyl-phenyl)-urea;

1-(2-Diethylamino-ethyl)-3-(4-trifluoromethyl-phenyl)-1-{2-[3-(4-trifluoromethyl-phenyl)-ureido]-ethyl}-urea;

1-(4-Bromo-phenyl)-3-{3-[1-(2-pyrrolidin-1-yl-ethyl)-3-(4-trifluoromethyl-phenyl)-thioureido]-propyl}-urea;

1-(2-Diisopropylamino-ethyl)-1-[2-(3-phenyl-ureido)-ethyl]-3-(4-trifluoromethyl-phenyl)-urea;

3-(4-Chloro-phenyl)-1-(2-pyrrolidin-1-yl-ethyl)-1-{2-[3-(3-trifluoromethyl-phenyl)-ureido]-ethyl}-urea;

1-(4-Chloro-phenyl)-3-{2-[3-(3-methoxy-phenyl)-1-(2-piperidin-1-yl-ethyl)-thioureido]-ethyl}-thiourea;

3-(4-Chloro-phenyl)-1-(2-pyrrolidin-1-yl-ethyl)-1-{2-[3-(4-trifluoromethyl-phenyl)-ureido]-ethyl}-urea;

1-{2-[3-(3-Chloro-phenyl)-ureido]-ethyl}-1-(3-diethylamino-propyl)-3-(4-trifluoromethyl-phenyl)-urea; and

1-(2-Diisopropylamino-ethyl)-3-(4-trifluoromethyl-phenyl)-1-{2-[3-(4-trifluoromethyl-phenyl)-ureido]-ethyl}-urea.

7-10 (Canceled)

11. (Currently Amended) A pharmaceutical composition comprising a compound according to ~~any one of claims 1-6~~ claim 1, admixed with one or more pharmaceutically acceptable excipients or carriers.

12. (Original) A pharmaceutical composition according to claim 11, wherein the excipients are chosen from the group comprising filling agents, lubricants, flavours, colourings, sweetenings, buffers, acidifying agents, diluents and preservatives.

13. (Currently Amended) A pharmaceutical composition according to ~~any one of claims 10-12~~ claim 10, which is administered orally, intramuscularly, intravenously, intraperitoneally or subcutaneously, via implants, rectally, intranasally, transdermally, topically, or parenterally.

14. (Currently Amended) A method of treatment comprising administration of a pharmaceutically effective amount of compound according to ~~claim 1-6~~ claim 1 or a pharmaceutical composition according to ~~claim 11-13~~ or a pharmaceutical composition comprising said compound with one or more pharmaceutically acceptable excipients or carriers to a subject suffering from an immune disorder which benefit from inhibition of production of IL-2 and other pro-inflammatory cytokines and/or induction of apoptosis in activated T-cells.

15. (Original) A method of treatment according to claim 14, wherein the immune disorder are chosen from the group comprising inflammatory diseases, autoimmune diseases, organ and bone marrow transplant rejection and other disorders associated with pro-inflammatory cytokines, especially IL-2, mediated immune response and defective cell regulation.

16. (Currently Amended) A method of treatment according to claim 14 or 15, wherein the immune disorders are chosen from the group comprising acute or chronic inflammation, rheumatoid arthritis, multiple sclerosis, type-1 diabetes, inflammatory bowel disease, psoriasis, graft versus host disease and malignant neoplastic disease.

17. (New) A compound according to claim 2, wherein
R1 is selected from dimethylamino, diethylamino, diisopropylamino, pyrrolidino, piperidino, 4-methyl-piperazino;
n is selected from 1 and 2;
m is selected from 2 and 3;
 $Y_{(1-3)}$ is one substituent selected from fluoro, chloro, bromo, trifluoromethyl, dimethylamino and diethylamino.

18. (New) A compound according to claim 3, wherein
R1 is selected from dimethylamino, diethylamino, diisopropylamino, pyrrolidino, piperidino, 4-methyl-piperazino;
n is selected from 1 and 2;
m is selected from 2 and 3;
 $Y_{(1-3)}$ is one substituent selected from fluoro, chloro, bromo, trifluoromethyl, dimethylamino and diethylamino.

19. (New) A compound according to claim 3, wherein
Ar is selected from phenyl, 2-naphthyl and 4-pyridyl,
n is selected from 1 and 2;
m is selected from 2 and 3;
 $Y_{(1-3)}$ is one of the substituents selected from fluoro, chloro, bromo, and trifluoromethyl.

20. (New) A compound according to claim 4, wherein

Ar is selected from phenyl, 2-naphthyl and 4-pyridyl,
n is selected from 1 and 2;
m is selected from 2 and 3;
 $Y_{(1-3)}$ is one of the substituents selected from fluoro, chloro, bromo, and trifluoromethyl.

21. (New) A pharmaceutical composition comprising a compound according to claim 2, admixed with one or more pharmaceutically acceptable excipients or carriers.

22. (New) A pharmaceutical composition comprising a compound according to claim 3, admixed with one or more pharmaceutically acceptable excipients or carriers.

23. (New) A pharmaceutical composition comprising a compound according to claim 4, admixed with one or more pharmaceutically acceptable excipients or carriers.

24. (New) A method of treatment according to claim 15, wherein the immune disorders are chosen from the group comprising acute or chronic inflammation, rheumatoid arthritis, multiple sclerosis, type-1 diabetes, inflammatory bowel disease, psoriasis, graft versus host disease and malignant neoplastic disease.